Spesolimab Production Cost Reports

The report provides a detailed analysis essential for establishing a spesolimab production plant. It encompasses all critical aspects necessary for spesolimab production, including the cost of spesolimab production, spesolimab plant cost, spesolimab production costs, and the overall spesolimab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a spesolimab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Spesolimab is a humanised monoclonal antibody that selectively inhibits the interleukin-36 receptor (IL-36R). It is approved for the treatment of generalised pustular psoriasis (GPP) flares in adults and pediatric patients aged 12 years and older weighing at least 40 kg. It is administered as a 900 mg intravenous infusion over 90 minutes for acute flares, with an optional second dose after one week if symptoms persist. It reduces pustule count and skin inflammation by blocking IL-36 signalling pathways. It is used in ulcerative colitis, Crohn's disease, palmoplantar pustulosis, and hidradenitis suppurativa. Its common side effects include asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site bruising and hematoma, and urinary tract infection.

The market for spesolimab is driven by rising awareness and diagnosis of generalised pustular psoriasis (GPP). The expanding regulatory approvals across regions like the US, Europe, Japan, China, etc., along with strategic partnerships contributes to its market growth. The increased healthcare expenditure supporting biologic therapies and expansion into other IL-36-mediated conditions like pyoderma gangrenosum fuels its market. The high costs of monoclonal antibody production requiring specialised biologic facilities, and cold-chain logistics complexities impact industrial spesolimab procurement. Its patent protections limiting generic entry, reimbursement challenges varying by market, and supply chain dependencies affect its market dynamics.

Raw Material for Spesolimab Production

According to the spesolimab production plant project report, the key raw materials used in the production of spesolimab include  Chinese hamster cells CHO cells with spesolimab DNA and serum-free basal and feed media.

Production Process of Spesolimab

The extensive spesolimab production cost report consists of the following major industrial production process:

1. From CHO cells: The production process of spesolimab involves genetically engineering CHO cells. These cells are grown in serum-free medium with optimised iron and low copper levels in a 12-21-day fed-batch culture at controlled pH, temperature, and oxygen. The culture supernatant is harvested and purified through protein A chromatography, viral inactivation, ion exchange, viral filtration, and hydrophobic interaction steps to get high-purity spesolimab.

Spesolimab has the molecular formula of C6480H9988N1736O2012S46 and an approximate molecular weight of 145.88–146 kDa. It works as a selective interleukin-36 receptor antagonist for treating generalised pustular psoriasis. It exhibits linear pharmacokinetics over doses of 0.3–20 mg/kg and a steady-state volume of distribution of 6.4 L. It has a terminal half-life of about 25.5 days and clearance of roughly 0.184 L/day in a typical 70 kg patient without anti-drug antibodies. It is formulated as a stable solution for intravenous or subcutaneous injection, with binding affinity characterised by a K_D of 24 pM.